As the malignant and heterogeneity nature of tumor, combination therapy might achieve a better treatment effect: one with HFn drug nanocarrier system targeted to TfR1-positive cells; the other with inhibitors antagonistic to TfR1-negative cells. Here, TFRC is linked to neoplasm.